SuperGen’s MP-470 Demonstrates Clinical Benefit In Lung Cancer Patients
SuperGen Inc., (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Phase Ib data for MP-470, its multi-targeted, tyrosine kinase inhibitor and RAD51 suppressor, demonstrated an overall clinical benefit rate of 54 percent when the drug is given in combination with standard of care (SOC) anti-cancer therapies in patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
More: continued here
Filed under: Cancer on May 6th, 2009
You must be logged in to post a comment.